Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Macular Diseases

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ophthalmol Retina

Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG

doi: 10.1016/j.oret.2025.05.030

Macular Diseases

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

J Clin Med

Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM, XTEND Study Group

doi: 10.3390/jcm14072370

Macular DiseasesRetinal Diseases

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Eye (Lond)

Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J, from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group

doi: 10.1038/s41433-024-03322-8

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Acta Ophthalmol

Butler ETS, Arnold-Vangsted A, Schou MG, Anguita R, Bjerager J, Borrelli E, Cehofski LJ, Ferro Desideri L, van Dijk EHC, Faber C, Grauslund J, Hajari JN, Huemer J, Klefter ON, Krogh Nielsen M, Sabaner MC, Schneider M, Subhi Y

doi: 10.1111/aos.17506

COMMENTED

Macular DiseasesRetinal Diseases

Psoriasis as a Predictor of Neovascular Age-Related Macular Degeneration in Type 2 Diabetes Mellitus: A Nationwide Cohort Study

★ 3 Recommended and commented by Prof. emer. Dr Josef Flammer, Faculty Member

Am J Ophthalmol

Lee MY, Han K, Min KH, Yu DS, Lee YB

doi: 10.1016/j.ajo.2024.08.033

Macular Diseases

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial

Ophthalmol Retina

Hamouz J, Nowosielska A, Święch-Zubilewicz A, Abengoechea S, Baumane K, Vajas A, Siewierska M, Veselovsky M, Veith M, Kerényi Á, Mange S, Baidya K, Laganovska G, Jürgens I, Papp A, Gosai J, Štefanickova J, Han M, Fryczkowski P, Zalewski D, Wang J, Wei W

doi: 10.1016/j.oret.2024.10.001

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Related content

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Psoriasis as a Predictor of Neovascular Age-Related Macular Degeneration in Type 2 Diabetes Mellitus: A Nationwide Cohort Study

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series